companydata.dkcompanydata.dk
Back to company

Salient Pharma ApS: Financial statements 2016

CVR: 36900709

Salient Pharma ApS (CVR 36900709) has filed annual accounts for 2016. In 2016, the company reported a gross profit of DKK -954,993 and a net result of DKK -772,477. Equity amounted to DKK -847,215.

Gross Profit
-954,993 kr.
Profit/Loss
-772,477 kr.
Equity
-847,215 kr.
Total Assets
592,309 kr.

Official annual report

View the official annual report directly on the page with a Pro subscription.

How creditworthy is Salient Pharma ApS?

See the CDS score and get a full credit report with recommended credit limit and payment terms.

Read about the CDS score

Events in 2016

Salient Pharma ApS publishes interim reportJun 9, 2016

Salient Pharma ApS has published its interim report for the period May 21, 2015 – December 31, 2015.

About Salient Pharma ApS

Salient Pharma ApS is a Danish company of the type Anpartsselskab based in Glostrup, founded in 2015. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The management consists of Ulrik Spork. The company is owned by HB-MEDICAL HOLDING ApS, CAND.PHARM. POVL M. ASSENS FOND and SPORCON LIFESCIENCE ADVISORS ApS. In 2025, the company reported a gross profit of DKK -129,889 and a net result of DKK -218,345 compared with DKK -202,180 the year before. Equity amounted to DKK -1,344,010.

Other financial years

202520242023202220212020201920182017